ImmunoGen, Inc. (IMGN) News

ImmunoGen, Inc. (IMGN): $5.64

-0.19 (-3.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

Filter IMGN News Items

IMGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMGN News Highlights

  • For IMGN, its 30 day story count is now at 9.
  • Over the past 27 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about IMGN are ADC and MD.

Latest IMGN News From Around the Web

Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

Antibody Drug Conjugates Market Expoler Future Growth With Top Key Players like Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc.

Antibody drug conjugate (ADC) is a class of biopharmaceutical drugs indicated as a targeted therapy for treating cancer. ADC is are designed to kill only cancer cells and spare healthy cells, which makes it more effective than traditional cancer treatment

OpenPR | October 19, 2021

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

WALTHAM, Mass., October 14, 2021--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

Yahoo | October 14, 2021

ImmunoGen: Important Catalysts Ahead

I covered ImmunoGen (IMGN) twice in the last couple years. In 2019, I discussed the company’s leadership position in ADC technology and its list of licensing partners. I discussed why it failed the FORWARD 1 trial, and the then soon-to-begin SOROYA trial in patients with high FRα expression. In my...

Avisol Capital Partners on Seeking Alpha | October 10, 2021

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., October 01, 2021--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | October 1, 2021

ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

Business Wire | September 22, 2021

Leerink Partners Stick to Their Hold Rating for Immunogen By Investing.com

Leerink Partners Stick to Their Hold Rating for Immunogen

Investing.com | August 6, 2021

ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.

Yahoo | August 2, 2021

ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript

At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.

Yahoo | July 30, 2021

ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2021

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

WALTHAM, Mass., July 30, 2021--ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

Yahoo | July 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 5.763 seconds.